Structure, function, and inhibition of drug reactivating human gut microbial β-glucuronidases

[1]  M. Redinbo,et al.  Gut Microbial β-Glucuronidase Inhibition via Catalytic Cycle Interception , 2018, ACS central science.

[2]  M. Redinbo,et al.  An Atlas of β-Glucuronidases in the Human Intestinal Microbiome. , 2017, Structure.

[3]  E. Balskus,et al.  Chemical transformation of xenobiotics by the human gut microbiota , 2017, Science.

[4]  M. Redinbo,et al.  Glucuronides in the gut: Sugar-driven symbioses between microbe and host , 2017, The Journal of Biological Chemistry.

[5]  R. Venkataramanan,et al.  Drug Metabolism in the Liver. , 2017, Clinics in liver disease.

[6]  F. Bäckhed,et al.  From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites , 2016, Cell.

[7]  R. Upton,et al.  A Quantitative Review and Meta-Models of the Variability and Factors Affecting Oral Drug Absorption—Part I: Gastrointestinal pH , 2016, The AAPS Journal.

[8]  S. Frye,et al.  Structure and Inhibition of Microbiome β-Glucuronidases Essential to the Alleviation of Cancer Drug Toxicity. , 2015, Chemistry & biology.

[9]  Heidi J. Imker,et al.  Enzyme Function Initiative-Enzyme Similarity Tool (EFI-EST): A web tool for generating protein sequence similarity networks. , 2015, Biochimica et biophysica acta.

[10]  Masataka Yoshino,et al.  Analysis of the substrate inhibition of complete and partial types , 2015, SpringerPlus.

[11]  M. Redinbo,et al.  Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics , 2014, Xenobiotica; the fate of foreign compounds in biological systems.

[12]  Christian Milani,et al.  Bacteria as vitamin suppliers to their host: a gut microbiota perspective. , 2013, Current opinion in biotechnology.

[13]  P. Cotter,et al.  Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ , 2013, Therapeutic advances in gastroenterology.

[14]  M. Redinbo,et al.  Multiple NSAID-induced hits injure the small intestine: underlying mechanisms and novel strategies. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[15]  H. Flint,et al.  Microbial degradation of complex carbohydrates in the gut , 2012, Gut microbes.

[16]  M. Redinbo,et al.  Pharmacologic Targeting of Bacterial β-Glucuronidase Alleviates Nonsteroidal Anti-Inflammatory Drug-Induced Enteropathy in Mice , 2012, Journal of Pharmacology and Experimental Therapeutics.

[17]  V. Schramm,et al.  Enzymatic transition states, transition-state analogs, dynamics, thermodynamics, and lifetimes. , 2011, Annual review of biochemistry.

[18]  Matthew R. Redinbo,et al.  Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme , 2010, Science.

[19]  P. Bork,et al.  A human gut microbial gene catalogue established by metagenomic sequencing , 2010, Nature.

[20]  Thomas E. Ferrin,et al.  Using Sequence Similarity Networks for Visualization of Relationships Across Diverse Protein Superfamilies , 2009, PloS one.

[21]  Abdul W Basit,et al.  The gastrointestinal microbiota as a site for the biotransformation of drugs. , 2008, International journal of pharmaceutics.

[22]  T. Gibson,et al.  Malectin: a novel carbohydrate-binding protein of the endoplasmic reticulum and a candidate player in the early steps of protein N-glycosylation. , 2008, Molecular biology of the cell.

[23]  Y. Pommier.  Topoisomerase I inhibitors: camptothecins and beyond , 2006, Nature Reviews Cancer.

[24]  F. Shanahan,et al.  The gut flora as a forgotten organ , 2006, EMBO reports.

[25]  Kim L R Brouwer,et al.  Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[26]  P. Tailliez,et al.  Genetic characterization of the beta-glucuronidase enzyme from a human intestinal bacterium, Ruminococcus gnavus. , 2005, Microbiology.

[27]  D. Bolam,et al.  Carbohydrate-binding modules: fine-tuning polysaccharide recognition. , 2004, The Biochemical journal.

[28]  A. Manni,et al.  Combined Irinotecan and Oxaliplatin in Patients with Advanced Pre-Treated Pancreatic Cancer , 2004, Oncology.

[29]  A. D. Rodrigues,et al.  Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[30]  J. Robert,et al.  Pharmacology of irinotecan. , 1998, Drugs of today.

[31]  A. Böhmer,et al.  Macrolides and community-acquired pneumonia: is quorum sensing the key? , 2010, Critical care.

[32]  M Nomura,et al.  Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. , 1996, Cancer research.